Article Data

  • Views 660
  • Dowloads 137

Reviews

Open Access

Multidisciplinary management of advanced ovarian cancer for an optimal therapeutic strategy

  • P.E. Heudel1,*,
  • M. Devouassoux-Shisheboran2
  • S. Taieb3
  • C. Genestie4
  • F. Selle5
  • P. Morice6
  • R. Rouzier7
  • I. Ray-Coquard1

1Medical Oncology Department, Centre Léon Bérard, Lyon, France

2Department of Anatomopathology, Hospices Civils de Lyon, Lyon

3Department of Radiology, Centre Oscar Lambret, Lille, France

4Department of Anatomopathology, Institut Gustave Roussy, Villejuif

5 Medical Oncology Service, Hôpital Tenon, Paris, France

6Department of Surgery, Institut Gustave Roussy, Villejuif, France

7Department of Surgery, Institut Curie, Paris, France

DOI: 10.12892/ejgo3392.2017 Vol.38,Issue 2,April 2017 pp.175-180

Published: 10 April 2017

*Corresponding Author(s): P.E. Heudel E-mail: pierre-etienne.heudel@lyon.unicancer.fr

Abstract

The management of advanced ovarian cancer generally requires specialist multidisciplinary teamwork to achieve optimum outcomes. Preoperative computed tomography scans are the imaging modality of choice in determining the extent of disease and aiding in surgical planning. Histological classification is crucial to define various subtypes with their different behaviour and prognosis and to plan the best therapeutic strategy. Pathological prognostic factors, such as histological type, degree of differentiation, and FIGO stage must be described. To determine the ability to optimally cytoreduce advanced ovarian cancer, an experienced gynaecological oncologist needs to explore the entire upper abdomen and the pelvic and para-aortic lymph node regions to define the peritoneal cancer index (PCI). The final assessment is the completeness of cytoreduction (CC) score which is important in predicting prognosis and decision of post-surgical surgery. Ovarian cancer is the leading cause of death from gynaecologic cancers. Initial management is best provided by a specialist multidisciplinary team, including a radiologist, a pathologist, a gynaecologic oncologist, and a medical oncologist.

Keywords

Advanced ovarian cancer; Initial staging; Multidisciplinary team.

Cite and Share

P.E. Heudel,M. Devouassoux-Shisheboran,S. Taieb,C. Genestie,F. Selle,P. Morice,R. Rouzier,I. Ray-Coquard. Multidisciplinary management of advanced ovarian cancer for an optimal therapeutic strategy. European Journal of Gynaecological Oncology. 2017. 38(2);175-180.

References

[1] EUCAN Cancer Factsheets: “ Ovary”. Available at: http://eco.iarc.fr/eucan/CancerOne.aspx?Cancer=27&Gender=2

[2] INCA: “Référentiels de bon usage hors GHS. Cancers gynécologiques”. March 2012. Available at: https://omedit.santera.fr/doc/omedit/RBU%20Cancers%20Gynecologiques.pdf [Article in French]

[3] INCA: “Cancer de l’ovaire -Traitement chirurgical”. June 2009. Availble at: http://www.ecancer.fr/content/download/95905/1021084/file/RECOOVA10.pdf [Article in French]

[4] Chi D.S., Eisenhauer E.L., Lang J., Huh J., Haddad L., Abu-Rustum N.R., et al.: “What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?” Gynecol. Oncol., 2006, 103, 559.

[5] Du Bois A., Reuss A., Pujade-Lauraine E., Harter P., Ray-Coquard I., Pfisterer J.: “Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials”. Cancer,2009, 115, 1234.

[6] HAS: “Guide ALD 30: Cancer de l’ovaire”. January 2010. Available at: http://www.has-sante.fr/portail/jcms/c_922802/fr/ald-n-30-cancer-de-l-ovaire [Article in French]

[7] Michielsen K., Vergote I., Op de Beeck K., Amant F., Leunen K., Moerman P., et al.: “Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT”. Eur. Radiol., 2014, 24, 889.

[8] Espada M., Garcia-Flores J.R., Jimenez M., Alvarez-Moreno E., De Haro M., Gonzalez-Cortijo L., et al.: “Diffusion-weighted magnetic resonance imaging evaluation of intra-abdominal sites of implants to predict likelihood of suboptimal cytoreductive surgery in patients with ovarian carcinoma”. Eur Radiol. 2013, 23, 2636.

[9] Fischerova D., Burgetova A.: “Imaging techniques for the evaluation of ovarian cancer”. Best Pract. Res. Clin. Obstet. Gynaecol., 2014, 28, 697.

[10] Coakley F.V., Choi P.H., Gougoutas C.A., Pothuri B., Venkatraman E., Chi D., et al.: “Peritoneal metastases: detection with spiral CT in patients with ovarian cancer”. Radiology, 2002, 223, 495.

[11] Salani R., Axtell A., Gerardi M., Holschneider C., Bristow R.E.: “Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer”. Gynecol. Oncol., 2008, 108, 271.

[12] Axtell A.E., Lee M.H., Bristow R.E., Dowdy S.C., Cliby W.A., Raman S., et al.: ‘Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer”. J. Clin. Oncol., 2007, 25, 384.

[13] Vergote I., Tropé C.G., Amant F., Kristensen G.B., Ehlen T., Johnson N., et al.: “Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer”. N. Engl. J. Med., 2010, 363, 943.

[14] Verleye L., Ottevanger P.B., Kristensen G.B., Ehlen T., Johnson N., van der Burg M.E., et al.: “Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial”. Eur. J. Cancer, 2011, 47, 57.

[15] Michault C., Ambrosetti D., Tudor G., Devouassoux-Shisheboran M., Bellocq J.-P., Michiels J.-F.: “Cancer de l’ovaire - Comptes rendus ACP des pièces d’exérèse pour tumeurs malignes et frontières de l’ovaire. Bilan d’une évaluation de l’AFAQAP sur 23 structures en 2011”. Annales de Pathologie, 2012, 32, pS154. [Article in French]

[16] McCluggage W.G., Lyness R.W., Atkinson R.J., Dobbs S.P., Harley I., McClelland H.R., Price J.H., et al.: “Morphological effects of chemotherapy on ovarian carcinoma”. J. Clin. Pathol., 2002, 55, 27.

[17] McCluggage W.G.: “Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis”. Pathology, 2011, 43, 420.

[18] Chang F., Deere H., Mahadeva U., George S.: “Histopathologic examination and reporting of esophageal carcinomas following preoperative neoadjuvant therapy: practical guidelines and current issues”. Am. J. Clin. Pathol., 2008, 129, 252.

[19] Traitements, soins et innovations, INCa: “Comptes rendus d’anatomopathologie: données minimales à renseigner pour une tumeur primitive”. Boulogne-Billancourt, December 2009. Available at: h t t p : / / w w w. s a n t e - l i m o u s i n . f r / t r a v a i l / r e s e a u x - d e -sante/rohlim/espace-professionnels-de-sante/etablissementsautorises-et-associes/cr-d-anatomopathologie-donnees-minimalesa-renseigner.pdf [Article in French]

[20] Malpica A., Deavers M.T., Lu K., Bodurka D.C., Atkinson E.N., Gershenson D.M., Silva E.G.: “Grading ovarian serous carcinoma using a two-tier system”. Am. J. Surg. Pathol., 2004, 28, 496.

[21] Malpica A.: “Grading of ovarian cancer: a histotype-specific approach”. Int. J. Gynecol. Pathol., 2008, 27, 175.

[22] Rodríguez I.M., Prat J.: “Mucinous tumors of the ovary: a clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas”. Am. J. Surg. Pathol., 2002, 26, 139.

[23] Chambrier C., Sztark F.; SFAR/SFNEP: “Recommandations de bonnes pratiques cliniques sur la nutrition périopératoire. Actualisation 2010”. avilable at: http://sofia.medicalistes.org/spip/IMG/pdf/Nutrition_perioperatoire_actualisation_des_recommandations.pdf [Article in French]

[24] Richardson D.L., Mariani A., Cliby W.A.: “Risk factors for anastomotic leak after recto-sigmoid resection for ovarian cancer”. Gynecol. Oncol., 2006, 103, 667.

[25] Classe J.M., Rouzier R., Glehen O., Meeus P., Bereder J.M., Rouzier R., Lecuru F.: “Cancer de l’ovaire et chimiothérapie néoadjuvante. In : Premières recommandations sur le cancer de l’ovaire”. Nice, Saint Paul de Vence, 2012. Available at: http://www.arcagy.org/arcagy-organisation-et-recherche/assets/files/espace-recherche-pdf/saint-paul-de-vence-2012/RECOGYNECO-COMPLET.PDF [Article in French]

[26] Tentes A.A., Tripsiannis G., Markakidis S.K., Karanikiotis C.N., Tzegas G., Georgiadis G., Avgidou K.: “Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer”. Eur. J. Surg. Oncol., 2003, 29, 69.

[27] Chéreau E., Ballester M., Selle F., Cortez A., Daraï E., Rouzier R.: “Comparison of peritoneal carcinomatosis scoring methods in predicting resectability and prognosis in advanced ovarian cancer”. Am. J. Obstet. Gynecol., 2010, 202, 178.e1.

[28] Prat J, FIGO Committee on Gynecologic Oncology: “Staging classification for cancer of the ovary, fallopian tube, and peritoneum”. Int. J. Gynaecol. Obstet., 2014, 124, 1.

[29] Tate S., Hirai Y., Takeshima N., Hasumi K.: “CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma”. Gynecol. Oncol., 2005, 96, 143.

[30] Le T., Faught W., Hopkins L., Fung-Kee-Fung M.: “Importance of CA125 normalization during neoadjuvant chemotherapy followed by planned delayed surgical debulking in patients with epithelial ovarian cancer”. J. Obstet. Gynaecol. Can., 2008, 30, 665.

[31] González-Moreno S., Kusamura S., Baratti D., Deraco M.: “Postoperative residual disease evaluation in the locoregional treatment of peritoneal surface malignancy”. J. Surg. Oncol., 2008, 98, 237.

[32] Kehoe S.: “Chemotherapy or upfront surgery for newly diagnosedadvanced ovarian cancer: results from the MRC CHORUS trial”. J. Clin. Oncol., 2013, 31, [abstract 5500].

[33] Heudel P.E., Cousin P., Lurkin A., Cropet C., Ducimetiere F., Collard O.: “Territorial inequalities in management and conformity to clinical guidelines for sarcoma patients: an exhaustive populationbased cohort analysis in the Rhône-Alpes region”. Int. J. Clin. Oncol., 2014, 19, 744.

[34] Bristow R.E., Chang J., Ziogas A., Anton-Culver H.: “Adherence to treatment guidelines for ovarian cancer as a measure of quality care”. Obstet. Gynecol., 2013, 121, 1226.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top